跳至主要内容
临床试验/NCT01542606
NCT01542606撤回不适用

Performance Proof of The Norma-Sense Gen 3 - Wearing Study

Common Sense1 个研究点 分布在 1 个国家开始时间: 2019年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
color status of the NORMA-SENSE gen 3 and the pH measurement.

研究概览

简要总结

This study was designed to validate the color appearance on the NORMA-SENSE gen 3 when comes into contact with vaginal secretions having an elevated pH level

详细描述

This study was designed to validate the color appearance on the NORMA-SENSE gen 3. The NORMA-SENSE gen 3 changes color when worn by the user and comes into contact with vaginal secretions having an elevated pH level, without false positives due to urine remains or incontinence. The study will also asses the physical comfort in using NORMA-SENSE gen 3 and the result reading clarity which includes the ability to visualize and interpret the NORMA-SENSE gen 3 results.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women, age 18 years or greater with or without symptoms of vaginal infection.
  • Subject is ready to sign the informed consent form.

排除标准

  • Subject is unable or unwilling to cooperate with study procedures.
  • Subject is currently participating in another clinical study.
  • Subject suffers from vaginal bleeding or is menstruating.
  • Subject that have had sexual relations within the last 12 hours.
  • Subject that applied local antiseptic or antibiotic or vaginal treatment within the last 3 days.
  • Subject that applied vaginal douching within 12 hours prior to the visit at the clinic.

研究组 & 干预措施

color status

Experimental

The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.

干预措施: NORMA-SENSE (Device)

结局指标

主要结局

color status of the NORMA-SENSE gen 3 and the pH measurement.

时间窗: 3 days

agreement between the color status of the NORMA-SENSE gen 3 as reported by the subject after using the panty liners, and the pH measurement with Nitrazine paper.

次要结局

  • physical comfort in using NORMA-SENSE gen 3 and the result reading clarity(3 days)

研究者

发起方
Common Sense
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastatic
EUCTR2008-007969-23-ESCelgene Corporation1,015
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs;
EUCTR2016-002808-19-PLAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.440
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs.ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.1Level: LLTClassification code 10047783Term: Vulvovaginal candidaSystem Organ Class: 100000004862
EUCTR2016-002808-19-ITAZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.440
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs;ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.0 Level: LLT Classification code 10047783 Term: Vulvovaginal candida System Organ Class: 100000054373
EUCTR2016-002808-19-BGA.C.R.A.F. S.p.A. (Aziende Chimiche Riunite Angelini Francesco)445
进行中(未招募)
1 期
Ensayo clínico, fase III, para conocer la seguridad y eficacia de Sativex® para el alivio sintomático de la espasticidad en sujetos con esclerosis múltiple (Fase A Simple ciego para conocer la respuesta, y fase B, doble ciego, aleatorizado, con grupos paralelos controlado con placeboEspasticidad en esclerosis múltiple
EUCTR2006-005910-11-ESGW Pharma Ltd.356